<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stepwise asthma management in infants and children &lt;4 years of age with recurrent wheezing&lt;sup&gt;*&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stepwise asthma management in infants and children &lt;4 years of age with recurrent wheezing<sup>*</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Stepwise asthma management in infants and children &lt;4 years of age with recurrent wheezing<sup>*</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" colspan="2">NAEPP<sup>¶</sup><br/> (≤4 years old)</td> <td class="subtitle1" colspan="2">GINA<br/> (≤5 years old)</td> <td class="subtitle1">Our approach<br/> (&lt;4 years old)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Asthma symptoms/impact</td> <td class="subtitle2">Therapy<br/> (all steps include SABA as needed)</td> <td class="subtitle2">Asthma symptoms</td> <td class="subtitle2">Therapy<br/> (all steps include SABA as needed)</td> <td class="subtitle2">Therapy<br/> (all steps include SABA as needed)</td> </tr> <tr class="divider_bottom"> <td>Intermittent: <ul class="decimal_heading"> <li>Daytime symptoms ≤2 days/week</li> <li>No nocturnal awakenings</li> <li>No interference with activities</li> <li>Exacerbations treated with OCS ≤1/year</li> </ul> </td> <td><strong>Step 1</strong> <ul class="decimal_heading"> <li>A short course of a daily ICS beginning at the start of a respiratory tract infection</li> </ul> </td> <td> <ul> <li>Infrequent wheezing with viral infections and little to no symptoms between illnesses</li> </ul> </td> <td> <p><strong>Step 1</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>SABA as needed</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Short course of ICS at onset of viral respiratory illness plus SABA as needed</li> </ul> </td> <td> <p><strong>Step 1</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>A short course of a daily medium-dose ICS beginning at the start of a respiratory tract infection plus SABA as needed</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>SABA as needed</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Mild persistent: <ul class="decimal_heading"> <li>Daytime symptoms &gt;2 but &lt;7 days/week</li> <li>Nocturnal awakenings 1 to 2/month</li> <li>Minor interference with activities</li> <li>Exacerbations treated with OCS ≥2 in 6 months or ≥4 episodes of wheezing lasting more than a day in a year plus risk factors for persistent asthma</li> </ul> </td> <td> <p><strong>Step 2</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily LTRA</li> </ul> </td> <td> <ul> <li>Asthma symptoms that require SABA treatment &gt;2 times/week on average for 1 month or ≥3 exacerbations/year</li> </ul> or <ul> <li>Treated more often than every 6 to 8 weeks with SABA but asthma diagnosis is in question<sup>Δ</sup></li> </ul> </td> <td> <p><strong>Step 2</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Daily LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Short course of ICS at onset of viral respiratory illness</li> </ul> </td> <td> <p><strong>Step 2</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Daily LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Intermittent low-dose ICS used whenever a SABA is used</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Moderate persistent: <ul class="decimal_heading"> <li>Daily symptoms</li> <li>Nocturnal awakenings 3 to 4/month</li> <li>Daily SABA use</li> <li>Some activity limitation</li> <li>Exacerbations treated with OCS ≥2 in 6 months or ≥4 episodes of wheezing lasting more than a day in a year plus risk factors for persistent asthma</li> </ul> </td> <td><strong>Step 3<sup></sup></strong><sup>◊</sup> <ul class="decimal_heading"> <li>Daily low-dose ICS-LABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily low-dose ICS plus LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS</li> </ul> </td> <td> <ul> <li>Asthma not well controlled on low-dose ICS</li> </ul> </td> <td> <p><strong>Step 3</strong><sup>§</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Double daily low-dose ICS</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS plus LTRA</li> </ul> </td> <td> <p><strong>Step 3</strong><sup>§</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS-LABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily low-dose ICS plus LTRA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Severe persistent: <ul class="decimal_heading"> <li>Symptoms throughout the day</li> <li>Nocturnal awakenings &gt;1/week</li> <li>Need for SABA several times/day</li> <li>Extreme limitation in activity</li> <li>Exacerbations treated with OCS ≥2 in 6 months or ≥4 episodes of wheezing lasting more than a day in a year plus risk factors for persistent asthma</li> </ul> </td> <td> <p><strong>Step 4</strong><sup>◊</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS plus LTRA</li> </ul> </td> <td> <ul> <li>Asthma not well controlled on doubled low-dose ICS</li> </ul> </td> <td> <p><strong>Step 4</strong><sup>§</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Continue doubled daily low-dose ICS</li> </ul> <p class="indent1">and</p> <ul class="decimal_heading"> <li>Refer to asthma specialist for evaluation</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Add-on LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Increase frequency of ICS dosing</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Add intermittent ICS for exacerbations</li> </ul> </td> <td> <p><strong>Step 4</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS plus LTRA</li> </ul> </td> </tr> <tr> <td rowspan="2"> <ul> <li>Step-up therapy for severe asthma that is poorly controlled</li> </ul> </td> <td> <p><strong>Step 5</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA</li> </ul> </td> <td rowspan="2"> </td> <td rowspan="2"> </td> <td> <p><strong>Step 5</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA</li> </ul> </td> </tr> <tr> <td> <p><strong>Step 6</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA plus OCS</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA and OCS</li> </ul> </td> <td> <p><strong>Step 6</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA plus OCS</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA and OCS</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Initial and step-up therapies are noted above. A higher level of initial therapy, with concurrent use of OCS in some cases, may be chosen if the patient presents with an acute exacerbation. Treatment may be stepped down if asthma is well controlled for at least 3 months and is stepped up 1 or 2 steps if asthma is not well controlled or is very poorly controlled. An alternative to stepping up therapy is to first try one of the alternative options in the same step. Before stepping up therapy, inhaler technique, adherence, and exposure to potential triggers (eg, allergens, tobacco smoke exposures) should be assessed along with evaluating for alternative and/or concomitant diagnoses.</div><div class="graphic_footnotes"><p>NAEPP: National Asthma Education and Prevention Program; 
        GINA: Global Initiative for Asthma; 
        SABA: short-acting beta agonist; 
        OCS: oral corticosteroid (glucocorticoid); 
        ICS: inhaled corticosteroid (glucocorticoid); 
        LTRA: leukotriene receptor antagonist; 
        LABA: long-acting beta agonist.</p>
<p>* Dosing is reviewed in other UpToDate topics and
    tables on the management of asthma in children.</p>
<p>¶ Theophylline, nedocromil, and cromolyn are not included in the table even though they were included in NAEPP. They are rarely used due to the availability of more effective options.</p>
<p>Δ In these patients, a 3-month trial of therapy is reasonable and will help confirm or refute the diagnosis of asthma.</p>
<p>◊ For children 4 years of age, refer to steps 3 and 4 in the UpToDate table for stepwise asthma management in children aged 5 to 11.</p>
    
    § Step-up therapy.</div><div class="graphic_reference">References:
    <ol>
<li>National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 Focused updates to the asthma management guidelines. National Heart, Lung, and Blood Institute, 2020. Available at: <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" target="_blank">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a> (Accessed on December 16, 2020).</li>
<li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available at: <a href="http://www.ginasthma.org" target="_blank">www.ginasthma.org</a> (Accessed on October 27, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 127785 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
